



Investigating the combined effect of ursolic acid and alpelisib on inhibiting cell proliferation and the expression of HIF1 α on 4T1 breast cancer cell line

Erfan Sheikhi¹, Mahmoudreza Aghamaali^{2*}, Shabnam Babataheri³

¹ Department of Biochemistry, Faculty of Basic Sciences, University of Guilan, Rasht, Iran

² Associate professor, Department of Biochemistry Faculty of Basic Sciences, University of Guilan, Rasht, Iran

³ Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran

*Corresponding author: Mahmoudreza Aghamaali, Address: Department of Biochemistry, Faculty of Basic Sciences, University of Guilan, Rasht, Iran, Email: Aghamaali@guilan.ac.ir, Tel: +989111832094

Abstract

Background & Aims: Alpelisib and Ursolic acid are two compounds that have been shown to have potential as anti-cancer agents. Alpelisib is a selective inhibitor of the PI3K pathway, while Ursolic acid is a natural pentacyclic triterpene compound found in various plants that reveals anti-cancer, antioxidant and anti-inflammatory characteristics. The hypoxia-inducible factor 1 α (HIF1 α) is a transcription factor that plays a key role in regulating tumor cell survival, apoptosis, tumorigenesis and growth in low-oxygen environments. This study aims to determine the effects of Ursolic acid and Alpelisib on the expression of HIF1 α gene on 4T1 cell line. **Materials & Methods:** In the current experimental study, IC₅₀ concentrations of both Ursolic acid and Alpelisib were determined on 4T1 cells. Then cells were treated with determined IC₅₀ concentrations of Ursolic acid, Alpelisib and the combination of half of the IC₅₀ concentration of both drugs for 24 hours. After the treatment, viability was assessed with MTT assay and the expression of HIF1 α gene was appraised by Real-time PCR. Finally, statistical analysis was accomplished by ANOVA using GraphPad Prism 8.4 software.

Results: The results of this study showed that the anti-proliferative effect of the drug combination was synergistic and concentration-dependent. The maximum decrease (74.17 % with UA and 64.04 % with Alp) in viability was observed in high doses of treatment with drugs. IC₅₀ values of Ursolic acid and Alpelisib were 168.314 μ M and 6.377 μ M, respectively. Based on the real-time PCR results, HIF1 α gene expression was significantly decreased in both single- treatment and combination groups, compared to the control group (P<0.05).

Conclusion: The results of this study showed that both Alpelisib and Ursolic acid alone or in combination with each other could have anti-cancer effects by reducing HIF1 α gene expression. Further studies are needed to determine the efficacy and safety of these compounds in vivo.

Keywords: 4T1 Cell Line, Alpelisib, Apoptosis, Breast Cancer, Ursolic acid

Received 08 May 2023; accepted for publication 13 June 2023

Introduction

Breast cancer is the most prevalent leading cause of mortality associated with cancer among females worldwide. Like most cancers, Breast cancer is clinically and molecularly a heterogeneous disease. Tumor types and molecular profile characteristics play an important role in choosing therapeutic strategies. Effective treatment of breast cancer

requires a multidisciplinary approach comprising surgery, radiotherapy, adjuvant and neoadjuvant therapy (1). Breast cancer is classified into five subtypes: luminal-A, luminal-B, normal-like, basal-like, and HER2-enriched (2). Mutations in specific genes such as HIF1 α , P53, CDKs etc probably increase the risk of breast cancer more than other genes (1).

Hypoxia is a feature in most of the solid tumors and is associated with poor prognosis in several cancer types, including breast cancer. The master regulator of the hypoxic response is the Hypoxia-inducible factor 1 α (HIF1 α). The basis for the association between hypoxia, tumorigenesis and malignant progression has been examined extensively at both the molecular and the cellular level. Hypoxia exerts direct effects on the expression of numerous gene products involved in processes such as angiogenesis, apoptosis, glycolysis and cell-cycle control, which are central to the survival and expansion of a malignant cell population in an oxygen-deficient circumstance (3). HIF1 α is a transcription factor that plays a key role in regulating the survival and growth of tumor cells in hypoxic environments. Therefore, inhibition of HIF1 α expression is an important target in cancer therapy (4).

On the other hand, Alpelisib as an FDA approved anti-cancer drug is used in combination with Fulvestrant for the treatment of metastatic breast cancer. Alpelisib belongs to the group of kinase inhibitors that are used to inhibit the overgrowth related to the PIK3CA and cancer cell multiplication. Studies have shown that Alpelisib can down-regulate HIF1 α gene expression in breast cancer cells. This effect may be due to the inhibition of the PI3K/Akt/ mTOR signaling pathway, which is known to activate HIF1 α gene expression (5, 6).

Ursolic acid is a natural pentacyclic triterpene compound found in a variety of plants which shows many beneficial effects such as anti-inflammatory, antioxidant, anti-apoptotic, and anti-carcinogenic effects. It exerts anti-carcinogenic effects by suppressing nuclear factor-kappa β (NF κ β) signaling and increasing the antioxidants level. Ursolic acid is used as an alternative treatment for cancer in this study. Ursolic acid and Alpelisib are two compounds that have been shown to have effects on gene expression, specifically on the HIF1 α gene. Some studies have shown that Ursolic acid inhibits HIF1 α expression in human hepatocellular carcinoma cells. HIF1 α plays a crucial role in regulating the body's response to hypoxia, or low oxygen levels, and is involved in a number of important cellular processes, including metabolism, cell growth, and differentiation (7, 8).

In the present study, it was hypothesized that Ursolic acid and Alpelisib may inhibit the proliferation of breast cancer cells in vitro, and may induce apoptosis via down regulation of HIF1 α to suppress the development of breast cancer.

Materials & Methods

Cell line and culture conditions:

4T1 cell line was purchased from Pasteur Institute of Iran. Cells were cultured in 75 flasks using RPMI 1640 medium (Gibco, USA) containing 10% FBS (Fetal Bovine Serum) (Biosera, France) and 1% (Penicillin-Streptomycin) (Gibco, USA) under conditions of 5% CO₂, humidity 90% and 37°C. The culture medium was changed three times a week and trypsin/EDTA solution was used to harvest the cells. Then the third passage cells were used for the next steps.

Medicines and their preparation and used concentrations:

Ursolic acid and Alpelisib were prepared from SIGMA-ALDRICH and MEDCHEM EXPRESS companies, respectively. The solvents used were 99% ethanol, PBS and DMSO. Cell cultures were divided into two test groups including mono-drug and dual-drug groups. In the single-drug group, concentrations of 25, 50, 100, 200, and 400 μ M of Ursolic acid and 0.5, 1, 2,

4, and 8 μ M of Alpelisib were used. Three groups without any additional solution, Ursolic acid solvent, and Alpelisib solvent were used as control groups.

Determination of effective dose:

The effective dose of Ursolic acid and Alpelisib was analyzed by MTT assay. The MTT test was repeated three times, and the average absorbance obtained from three repetitions of the MTT test was included in the vital power formula. The IC₅₀ value of each drug was determined using Compusyn software, and the corresponding graph was drawn with GraphPad Prism software.

Real-time PCR:

Concentrations equal to IC₅₀ for single-drug groups and half of IC₅₀ concentration for two-drug groups were used to investigate gene expression by Real-time PCR method. 3 \times 10⁶ cells were used in the culture medium for each group. After incubation for 24 hours, cells were washed with PBS buffer, and total RNA was extracted by Hybrid-R kit (GeneAll, South Korea) according to the company's instructions. cDNA synthesis was performed using a commercial kit (YektaTajhiz, Iran) according to the manufacturer's protocol. The Real-time PCR reaction was performed using the primers for GAPDH as housekeeping gene and HIF1 α as the target gene given in table 1 and according to the information given in table 2.

Table 1. Characteristics of primers used in Real-Time PCR

Gene	Forward primer sequence	Reverse primer sequence	Primer length	Temperature (°C)
GAPDH	CAACTCCCCTCTCCACCT	GAGTTGGGATAGGGCCTCTC	205	60
HIF1 α	TCAGCATACAGTGGCACTCA	AAGGGAGCCATCATGTTCCA	213	60

Table 2. Device program for Real-Time PCR reaction

Step	Time	Temperature (°C)	Cycle
Primary denaturation	10 minutes	94	1
DENATURATION	30"	94	40
Annealing	60"	60	
elongation	60"	72	
final elongation	10"	72	1

The fold change of HIF1 α gene expression in different groups was calculated using the 2- $\Delta\Delta$ CT formula.

Statistical analysis:

Statistical analysis performed using GraphPad Prism version 8.4 software. Values are shown as means \pm S.D. One-way ANOVA was performed to determine the significance between groups. Confidence limits for all tests were considered 95% and P < 0.05 were considered to indicate a significant difference.

Results

The IC₅₀ values of Ursolic acid and Alpelisib were 168.314 μ M and 6.377 μ M, respectively.

It was observed that 168.314 μ M Ursolic acid and 6.377 μ M Alpelisib markedly suppressed breast cancer cell viability in 4T1 cell line in a concentration-dependent manner (P<0.05).

Based on these results, all subsequent experiments were performed using IC₅₀ concentration for single treatment and 1/2 IC₅₀ for combination groups. The results of cell viability based on MTT assay are shown in Figure 1.




Fig. 1. Shows an anti-proliferative effects of Ursolic acid and Alpelisib on the 4T1 cells. The inhibitory effects of Ursolic acid and Alpelisib with different concentrations after 24 h incubation. Results are expressed as percent of cell proliferation of control at 0 h. The data shown are the mean from three independent experiments, each with triplicate wells. The result indicates a significant difference between control and single drug-treatment cells as analyzed by Dunnett's test ($P < 0.05$). The IC_{50} values of Ursolic acid and Alpelisib were 168.314 μ M and 6.377 μ M, respectively.

Treatment of cells with IC_{50} concentration of Alpelisib and Ursolic acid led to a significant decrease in HIF1 α gene expression compared to the control group. The decrease in the expression of HIF1 α in the single-treatment and combination-treatment groups was

statistically significant, compared to the control group. These results probably indicate that the effect of these drugs on viability and growth of cancer cells by directing these cells towards apoptosis by regulating the genes involved in the PI3K/AKT/mTOR signaling pathway.




Fig. 2. Expression of HIF1 α in single treatment and combination of drugs on 4T1 cells. Cells were cultured with 168.314 μ M UA and 6.377 ALP for 24-h, and total RNA was isolated. Real-time PCR was performed using SYBR Green I as the detection dye after reverse transcription with Oligo (dT) primers. Ct was measured, and HIF1 α expression was presented as $2^{-\Delta Ct}$, with $\Delta Ct = Ct \text{ HIF1}\alpha - Ct \text{ GAPDH}$. Compared with vehicle control, HIF1 α mRNA was significantly decreased in single-treatment groups and combination groups ($^*P < 0.05$). Data are expressed as the mean \pm standard error of the mean. Values given were derived from the average of at least three independent experiments. $^*P < 0.05$, $^{**}P < 0.01$, $^{***}P < 0.001$ and, $^{****}P < 0.0001$ denote means significantly different from untreated cells.

Table 3. The results of One Way ANOVA based on Tukey's test according to alpha coefficient (0.05) for HIF1 α gene. Tukey's test is used to compare the mean variances of groups. Also, this test indicates the overall error.

Test details	Mean diff	SE of diff	95.00% CI of diff	P value
Control VS. Alp	0.8823	0.01783	0.8177 to 0.9468	****<0.0001
Control VS. UA	0.8663	0.01783	0.8017 to 0.9308	****<0.0001
Control VS. Alp+UA	0.9632	0.01783	0.8987 to 1.028	****<0.0001

Discussion

Hypoxia occurs in most solid tumors, and has been associated not only with malignant progression and poor prognosis but also with specific resistance to anti-cancer therapies. In normal cells, the level of HIF1 α is not much enough to measure accurately. Therefore, increasing its expression indicates that HIF1 α plays a critical role in tumor progression and expansion (3, 9).

Biochemical analyzes have shown that tumor suppressor p53 could directly interact with HIF1 α . Thus, HIF1 α stabilizes p53 and induces apoptosis in hypoxia conditions. On the other hand, it has been shown that HIF1 α has a stronger role than P53 in inducing cell cycle arrest (10). Alpelisib is FDA approved, orally active, and highly selective inhibitor of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. This pathway is known to regulate the expression of hypoxia-inducible factor-1 alpha (HIF1 α), which plays a crucial role in the cellular response to hypoxia or low oxygen levels. HIF1 α is involved in various cellular processes, such as angiogenesis, erythropoiesis, glucose metabolism, and many others (6, 11).

On the other hand, Ursolic acid is a natural pentacyclic triterpenoid that has been shown to have various pharmacological properties. Recent studies have revealed that Ursolic acid can suppress the PI3K/Akt signaling pathway, which is downstream of PI3K and further contributes to the regulation of HIF1 α (8, 12).

In previous studies, HT-29 colorectal carcinoma cell line was treated with a combination of Ursolic acid and oxaliplatin; the combination of drugs significantly inhibited p-AKT. Cells treated with the combination of drugs showed the significant tumor inhibition, indicating the potential of Ursolic acid to exert a synergistic effect in combination with other drugs (13).

Several research studies have suggested that both Alpelisib and Ursolic acid can modulate the expression of HIF1 α , either directly or indirectly. For instance, a study by Kuroda et al. (2020) reported that treatment with Alpelisib reduced the expression of HIF1 α in triple-negative breast cancer cells, which are known to be highly dependent on PI3K/mTOR signaling for their growth and survival. The authors suggested that Alpelisib could be a promising therapeutic option for these types of cancers by targeting the HIF1 α pathway (14).

Similarly, other studies demonstrated that Ursolic acid treatment inhibited the expression of HIF1 α and downstream targets in prostate cancer and hepatocellular carcinoma cells. In addition, different classes of terpenoids produce a synergistic effect when combined with standard chemotherapeutic agents or targeted agents. The researchers proposed that Ursolic acid could exert its anti-tumor effects by disrupting the PI3K/Akt/HIF1 α axis, which plays a crucial role in tumorigenesis and angiogenesis (15). The inhibitory effect of Alpelisib and Ursolic acid on different cell lines has also been studied. The inhibitory effect of Ursolic acid on MCF7 cell line has been shown by researchers. In addition, the induction of apoptosis of HT-29 cells by Ursolic acid has been shown in the study of Chen et al. Chteinberg et al. have shown the effect of Ursolic acid alone and in combination with Navitoclax on the induction of apoptosis in MCC cell line. Suppression of HIF1 α gene by Ursolic acid in other cell lines such as Hep3B, Huh7, RKO, LoVo, SW480, and HA22T has also been shown in other studies (16). Ursolic acid and Alpelisib has been used in separately with other drugs and in some cases, it has shown synergistic effects. Based on previous researches, the combination of Alpelisib with MCL1 inhibitor (s63845) and Fulvestrant

have significant synergistic effects in inhibiting the growth of cancer cells (8, 17-19).

In the current study, we hypothesized that UA induced its anti-tumor effect by regulating the expression of HIF1 α . Real-time PCR analysis confirmed that HIF1 α mRNA expression was decreased in both single-treatment and mix-treatment groups in 4T1 cells. This finding reveals that Ursolic acid and Alpelisib down regulate the expression of the HIF1 α in 4T1 cells, leading to inhibition of PI3K/Akt axis and subsequent apoptosis induction via regulation of downstream elements.

Taken together, both Ursolic acid and Alpelisib, demonstrated strong effect on viability of 4T1 breast cancer cell line and gene expression on HIF1 α . These findings suggest that relevant compounds could be potential therapeutic options for hypoxia-related diseases and cancers that are regulated by the HIF1 α pathway. Further studies are required to establish the mechanism of reactions between related drugs and other pathways. Furthermore, these findings should be evaluated with in vivo animal models, which can facilitate and accredit the in vitro results.

Acknowledgments

No Declared

Conflict of interest

No conflict of interest declaration between the authors.

Funding/support

No funding source.

References

- Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. *lancet oncol* 2001;2(3):133-40.
- Azim HA, Partridge AH. Biology of breast cancer in young women. *Breast Cancer Res* 2014;16(4):1-9. <https://doi.org/10.1186/s13058-014-0427-5>
- Favaro E, Lord S, Harris AL, Buffa FM. Gene expression and hypoxia in breast cancer. *Genome Med* 2011;3:1-12. <https://doi.org/10.1186/gm271>
- Corcoran SE, O'Neill LA. HIF1 α and metabolic reprogramming in inflammation. *J Clin Investig* 2016;126(10):3699-707. <https://doi.org/10.1172/jci84431>
- Li H, Prever L, Hirsch E, Gulluni F. Targeting PI3K/AKT/mTOR signaling pathway in breast cancer. *Cancers* 2021;13(14):3517. <https://doi.org/10.3390/cancers13143517>
- Chang D-Y, Ma W-L, Lu Y-S. Role of Alpelisib in the treatment of PIK3CA-mutated breast Cancer: patient selection and clinical perspectives. *Ther Clin Risk Manag* 2021:193-207. <https://doi.org/10.2147/term.s251668>
- Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G, Bishayee A. Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. *Biochem. Pharmacol* 2013;85(11):1579-87. <https://doi.org/10.1016/j.bcp.2013.03.006>
- Kashyap D, Tuli HS, Sharma AK. Ursolic acid (UA): A metabolite with promising therapeutic potential. *Life Sci* 2016;146:201-13. <https://doi.org/10.1016/j.lfs.2016.01.017>
- Semenza G. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. *Curr Pharm Des* 2009;15(33):3839-43. <https://doi.org/10.2174/138161209789649402>
- Goda N, Dozier SJ, Johnson RS. HIF-1 in cell cycle regulation, apoptosis, and tumor progression. *Antioxid Redox Signal* 2003;5(4):467-73. <https://doi.org/10.1089/152308603768295212>
- Choi YH, Jin GY, Li LC, Yan GH. Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/Akt/mTOR/HIF-1 alpha/VEGF pathway. *PLoS One* 2013;8(11):e81773. <https://doi.org/10.1371/journal.pone.0081773>
- Iqbal J, Abbasi BA, Ahmad R, Mahmood T, Kanwal S, Ali B, et al. Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future

- implications. *Biomed Pharmacother* 2018;108:752-6.<https://doi.org/10.1016/j.biopha.2018.09.096>
13. Shan J, Xuan Y, Zhang Q, Zhu C, Liu Z, Zhang S. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer. *Protein Cell* 2016;7(8):571-85.<https://doi.org/10.1007/s13238-016-0295-0>
14. Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. *Cell Death Dis* 2020;11(9):797.<https://doi.org/10.1038/s41419-020-02998-6>
15. Book: Kumar AP, et al. *Complementary and Alternative Medicines in Prostate Cancer. A Comprehensive Approach*. 1 th ed. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2016:93-110.
16. Kassi E, Sourlingas T, Spiliotaki M, Papoutsis Z, Pratsinis H, Aligiannis N, et al. Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells. *Cancer Invest* 2009;27(7):723-33.<https://doi.org/10.1080/07357900802672712>
17. Gómez Tejeda Zañudo J, Mao P, Alcon C, Kowalski K, Johnson GN, Xu G, et al. Cell Line-Specific Network Models of ER+ Breast Cancer Identify Potential PI3K α Inhibitor Resistance Mechanisms and Drug Combinations. *Cancer Res* 2021;81(17):4603-17.<https://doi.org/10.1158/0008-5472.can-21-1208>
18. Shan J-z, Xuan Y-y, Zheng S, Dong Q, Zhang S-z. Ursolic acid inhibits proliferation and induces apoptosis of HT-29 colon cancer cells by inhibiting the EGFR/MAPK pathway. *J Zhejiang Univ Sci B* 2009;10:668-74.<https://doi.org/10.1631/jzus.b0920149>
19. Shan J-z, Xuan Y-y, Zhang Q, Huang J-j. Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1 α . *J Zhejiang Univ Sci B* 2016;17(9):672.<https://doi.org/10.1631/jzus.b1600266>

This is an open-access article distributed under the terms of the [Creative Commons Attribution-noncommercial 4.0 International License](https://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, as long as the original work is properly cited.